Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Investor's Business Daily on MSN6d
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Exact Sciences price target lowered to $75 from $85 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Yahoo Finance4d
Exact Sciences’ forecast cut shocks analysts
Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...
Exact Sciences Stock Falls After Cutting Outlook, Posting Lower-Than-Expected 3Q Results
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.
Exact Sciences: Long-Term Growth Prospects Intact Despite Short-Term Challenges
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
Nasdaq7d
Exact Sciences Announces Third-Quarter 2024 Results
(2) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common ...
Morningstar7d
Exact Sciences Earnings: Fair Value Estimate Reduced on Weak Results and Lower Guidance
Exact Sciences reported revenue for the third quarter that disappointed expectations and lowered its full-year guidance. The midpoint of the updated revenue guidance range is $2.74 billion ...